RBC Capital Maintains Outperform on Pacira BioSciences, Lowers Price Target to $58
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Gregory Renza maintains an Outperform rating on Pacira BioSciences (NASDAQ:PCRX) but lowers the price target from $67 to $58.

November 03, 2023 | 7:15 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
RBC Capital maintains an Outperform rating on Pacira BioSciences but lowers the price target from $67 to $58.
The news is directly related to Pacira BioSciences. While the Outperform rating is maintained, the lowering of the price target could indicate a potential decrease in the short-term stock price. However, the overall impact is neutral as the Outperform rating suggests that the stock is still expected to do better than the market.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100